Article: Product Supply Issues Expected To Impact Nabi's Q3 Pharmaceutical Results; Results from StaphVAX Phase III Clinical Trial To Be Presented at ICAAC.

BOCA RATON, Fla., Sept. 19 /PRNewswire/ --

Nabi (Nasdaq: NABI) announced today that earnings from its pharmaceutical operations for the third quarter of 2000 will be adversely affected by limited availability of products manufactured for the company by Cangene Corporation. Nabi markets WinRho SDF(R) (RhoD Immune Globulin (Human)) in the United States under a profit sharing agreement with Cangene, which owns and manufactures the product. Cangene is also the contract manufacturer for Nabi-HB(TM) (Hepatitis B Immune Globulin (Human)).

Cangene initiated development of clinical lots of a new product at its facility in Canada earlier in 2000. This new product ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!